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RNA interferencerface glycoprotein whose physiological role remains elusive, while its implication
in transmissible spongiform encephalopathies (TSEs) has been demonstrated. Multiple interactions between
the prion protein and viruses have been described: viruses can act as co-factors in TSEs and life cycles of
different viruses have been found to be controlled by prion modulation.
We present data showing that human Adenovirus 5 induces prion expression. Inactivated Adenovirus did
not alter prion transcription, while variants encoding for early products did, suggesting that the prion is
stimulated by an early adenoviral function. Down-regulation of the prion through RNA interference showed
that the prion controls adenovirus replication and expression.
These data suggest that the prion protein could play a role in the defense strategy mounted by the host
during viral infection, in a cell autonomous manner. These results have implications for the study of the prion
protein and of associated TSEs.
© 2008 Elsevier Inc. All rights reserved.Introduction
The human prion gene (PRNP) contains two exons, of which a
single one codes for the protein (PrPC). This is a glycophosphatidy-
linositol anchored cell surface glycoprotein normally associated with
neurons, but expressed in many tissues, including, in humans, spleen,
kidney, stomach, blood and muscle (Linden et al., 2008 and references
therein). Control of PRNP expression has been attributed to sequences
in the 5′ and 3′ untranslated regions. No TATA box was identified
linked to the gene, which, together with the presence of CpG islands
and of Sp1 binding sites, suggests that PRNP is a housekeeping gene
(Mahal et al., 2001). Nevertheless, several studies have indicated that
PRNP expression can be modulated both by chromatin structure and
by transcription factors (Cabral et al., 2002; Linden et al., 2008; Zawlik
et al., 2006).
Some information on the functions performed by PrPC has been
derived from knock-out mice (Prn-p−/−). Six lines of Prn-p−/−mice were
developed based on different genetic constructs: they are all resistant
to the TSE associated with the PrPC conformer PrPSc, but display
normal development and behavior. Neurodegeneration in three of
these mouse lines (with a deletion extending to mouse Prn-p exon 3)Molecular Biology, “Sapienza”
x: +39 06 4456866.
o).
l rights reserved.has been related to alterations in the expression of the PrPC like
protein Doppel, rather than to the absence of PrPC itself (Bueler et al.,
1993; Bueler et al., 1992; Kuwahara et al., 1999; Manson et al., 1994;
Moore and Melton, 1997; Sakaguchi et al., 1996; Weissmann and
Aguzzi, 1999). Mice overexpressing wild type PrPC display different
phenotypes, according to the genetic construct chosen for transgen-
esis. Neurodegeneration, including ataxia and paralysis, has been
observed in mice engineered with a large part of the Prn-p gene
(reviewed in Martins et al., 2002 and Linden et al., 2008).
Studies at the cellular level have suggested that PrPC is implicated
in basic cellular processes, such as proliferation, differentiation and
apoptosis. Immortalized hippocampal neurons from Prn-p−/− mice are
more susceptible to apoptotic and oxidative stress (Kuwahara et al.,
1999). In contrast, other studies have suggested that PrPC can exert
proapototic functions (Paitel et al., 2002). Conditions for either
cytoprotective or proapoptotic effects of PrPC have been related to
the experimental system chosen to assay PrPC bioactivity (Linden
et al., 2008).
It has been suggested that PrPC may be involved in modulating the
intracellular levels of Ca++ via interactionwith Ca++ channels (Whatley
et al., 1995), in activating T-cell lymphocytes (Cashman et al., 1990), in
acting as a major transporter of Cu++ ions, since PrPC binds copper via
its unique octapeptide sequence repeats (Brown et al., 1997; Rachidi et
al., 2003), and in mediating signal transduction (Mouillet-Richard
et al., 2000; Spielhaupter and Schatzl, 2001).
Fig. 1. Ad5 induces PRNPmRNA and protein expression. a) Cells were infected with Ad5
at a moi of 1000, mRNA was collected at 18 (black bars) and 48 h (grey bars) p.i., PrPC
mRNAwas monitored by quantitative PCR. Results are normalized to GAPDH values and
expressed as relative fold change, with an arbitrary value of 1 assigned to the mock
sample collected at the 18 h time point. Ad5 versus mock, both at 18 and 48 h p.i.:
pb0.01. b) Cells were infected with Ad5 at a moi of 1000 or of 4000, protein extracts
were collected at 18 h p.i. and analyzed by western blotting using an anti-PrPC antibody
and an anti-β tubulin antibody as internal control. Normalized signals from infected
samples correspond to a 3 and 3.6fold change for the moi 1000 and 4000, respectively,
as compared to mock. c) FACS analysis of PrPC was performed on cells infected with Ad5
at a moi of 1000 (black bars) or mock treated (grey bars). Significant activation of PrPC
was observed at 12 and 14 h p.i. Quantitative PCR and FACS data are expressed as mean
values of two experiments with triplicate samples; SD is shown. Altogether the data
indicate that Ad5, starting from 12 h p.i., up-regulates total and membrane PrPC
expression.
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few years on PrPC. Nevertheless, while PrPC involvement and that of its
pathological conformer PrPSc into TSEs has been conclusively assessed
(Cashman and Caughey, 2004; Legname et al., 2004; Prusiner et al.,
1998; Roucou and LeBlanc, 2005; Weissmann and Aguzzi, 2005), the
precise physiological role of this protein remains elusive.
Different sets of experimental data published over the past few
years have attracted our attention with regard to the mutual
interaction between PrPC (or PrPSc) and viral infection.
Experiments in Prn-p−/− mice derived brain cells have shown that
Coxsackievirus B3 replication is more effective in Prn-p−/− cells,
possibly as a consequence of a retarded type I interferon response
attributed to the absence of PrPC (Nakamura et al., 2003). Vesicular
stomatitis virus injection in mice has been shown to induce a strong
increase in PrPC in the follicular dendritic cell network (Lotscher et al.,
2003), which has been linked to endogenous retrovirus activation and
control (Lotscher et al., 2007). Recent experiments in Prn-p−/− mice
have shown that PrPC may play certain roles in induction of
inflammation and inhibition of apoptosis in relation to infection
with the encelophalomyocarditis virus B variant (Nasu-Nishimura et
al., 2008). These results suggest an antiviral role for PrPC. A specific
situation has been described for Herpes simplex virus, type I: in vivo,
lack of PrPC expression has been linked to the establishment of Herpes
simplex virus type 1 latency, whereas viral replication has been
related to its over-expression (Thrackay and Budjoso, 2002b).
Viruses have been proposed as co-factors involved in the spread of
the prion related TSE, scrapie (Leblanc et al., 2006). Retroviral
infections enhance the release of scrapie infectivity in the supernatant
of co-infected cells. In the same line, adenoviral infection has been
implicated in scrapie: a study has in fact indicated that mouse
adenoviral infection accelerates the onset of scrapie disease in vivo
(Ehresmann and Hogan, 1985).
From the micro-array analysis of wild type Adenovirus 5 (Ad5)
infected human cells we observed the up-regulation of PRNP
expression (Piersanti et al., 2004). Given the specific knowledge
available on adenoviral products and on their effects on the host, and
since the full characterization of the biological processes related to
PrPC, as well as their contribution to the onset of viral infection are still
under investigation, we decided to make a thorough examination of
Ad5 PrPC reciprocal interaction in human cells.
The genome of Ad5 consists of a linear 36 kb double stranded
DNA molecule. Both strands are transcribed and code for a range of
viral proteins that are expressed in temporal succession: the early-
activated genes express the proteins involved in viral replication
(E2A and E2B) and host/virus interaction (E1, E3 and E4), while the
late-activated genes code for structural viral proteins (L1–L5).
Adenoviral E1A (12s and 13s), E1B (19K and 55K) and E4 (orfs 1,
2, 3, 4, 6, 3/4 and 6/7) products play a dominant role in the in vitro
remodeling of the host biology. E1A proteins inactivate the pRb
checkpoint, allowing the E2F transcription factor to activate genes
involved in nucleotide metabolism and DNA replication which are
required in the S phase. E1A also interacts with transcriptional
modulators, including histone acetyltransferases, histone deacety-
lases, and other chromatin remodeling factors (Ben-Israel and
Kleinberger, 2002). These interactions affect the transcription of
several cellular and viral genes, some of which are involved in cell
cycle control (Gallimore and Turnell, 2001). Cell cycle deregulation
by E1A results in stabilization and accumulation of p53. To prevent
cell cycle arrest and the apoptosis triggered by p53, the adenoviral
E1B and E4 gene products employ various mechanisms to
inactivate the tumor suppressor. The E1B 55K protein binds p53
and blocks its transcriptional activity (Martin and Berk, 1998), and,
in combination with the E4 orf6 product, promotes p53 degrada-
tion (Querido et al., 2001a; Querido et al., 2001b). The adenoviral
Bcl-2 homologue E1B 19K inhibits TNF-alpha-mediated apoptosis,
interacting with Bax (Sundararajan and White, 2001). On the top ofE4 orf6, the E4 region encodes a set of proteins interacting with
diverse cell products (Ben-Israel and Kleinberger, 2002; Bridge and
Ketner, 1989), including the E4 orf3 which relocalizes the Mre11–
Rad50–Nbs1 (MRN) complex, a process required for viral replica-
tion (Evans and Hearing, 2005), and the E4 orf4 which associates
with protein phosphatase 2A, regulating apoptosis (Shtrichman
et al., 1999).
In the present work we report on the effect of wild type Ad5 on
PRNP expression and vice versa. We present data showing that Ad5
early gene expression is responsible for PRNP induction. We show that
a UV-inactivated adenoviral genome and an E1/E3-deleted adenovirus
do not alter PRNP transcription, while adenoviral variants selectively
deprived of the E1B (19K or 55K), or of the E4 products, exert a PRNP
inducing activity. We also present data to the effect that PrPC down-
regulation through RNA interference significantly enhances Ad5
replication and expression.
These results suggest that PRNP is stimulated by Ad5 infection and
that this effect is a specific response by the cell to an early adenoviral
function, which could be related to the E1A products; the attenuation
of this response through PrPC down-regulation allows the adenoviral
life cycle to proceed more vigorously.
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PRNP induction by Ad5
Several published data attracted our interest concerning the
mutual interaction between PrPC (or PrPSc) and viral infection (Leblanc
et al., 2006; Nakamura et al., 2003; Nasu-Nishimura et al., 2008;
Thrackay and Budjoso, 2002b). In particular, from gene chip studies
we observed that Ad5 infection up-regulates PRNP 7fold in human
cells at 12 h p.i. (Piersanti et al., 2004). To analyze this interactionmore
thoroughly, we infected human cells with Ad5 and performed
quantitative PCR, western blotting and FACS analysis on PrPC at
various times p.i. We observed that Ad5 indeed significantly increased
PRNP expression: this was detected both at 18 and at 48 h p.i.
(respectively: ∼6fold and ∼4fold change Ad5 versus mock treated
cells; Fig. 1a). PRNP induction was detected also at the protein level:
Ad5 induced the accumulation of total-cytosolic and membrane PrPC
(Fig. 1b). FACS analysis of infected cells showed that Ad5 also induces
an increase in membrane PrPC, at the 12 and 14 h time points (Fig. 1c).
At 18 h p.i. no further increase in membrane PrPC was observed in Ad5
treated cells as compared to mock specimens. Altogether, these data
confirm that Ad5 up-regulates membrane PrPC expression and
induces PrPC cytosolic accumulation, presumably as a consequence
of the observed transcriptional induction.
PRNP activation by Ad5 could be related to a general stress
response by the cell to microbial invasion, i.e. a response to viral DNA
or to input viral proteins, or to a specific reaction of the cell to
adenoviral gene expression. In order to distinguish between these two
scenarios, we infected human cells with Ad5, with the genetically
attenuated Ad5 H14 (dlE1E3), or with physically inactivated (UV-Fig. 2. Active adenoviral infection is needed for PRNP induction. a) HuH7 cells were
infected with Ad5, or dlE1E3 Ad5 (H14) at a moi of 1000 (black bars) or 10,000 (grey
bars) or mock treated. b) HUVEC (human umbilical vein endothelial) cells were infected
with Ad5 (black bar) and UV-inactivated Ad5 at a moi of 1000 (grey bar), or mock
treated (white bar). In both cell systemsmRNAwas collected at 18 h p.i. and PRNPmRNA
was monitored by quantitative PCR. Results are normalized to GAPDH values and
expressed as relative fold change, assigning to mock samples an arbitrary value of 1.
Data are expressed as mean values of two experiments with duplicate samples; SD is
shown. Ad5 versus mock in a) and in b): pb0.01. Only wild type Ad5 induces PRNP
transcription both in HuH7 and in primary cells (HUVEC), while neither the genetically
attenuated adenovirus (H14) nor the UV-inactivated virus induces its modulation, even
when used at high dosage (moi 10,000).
Fig. 3. Characterization of viral gene expression in HuH7 infected with differently
deleted adenoviral mutants. Cells were infected with Ad5, or with the adenoviral
mutants dl1004 (dlE4), dl520 (dlE1A 13s), dl1520 (dlE1B 55K), dl337 (dlE1B 19K) at a
moi of 1000. mRNA was collected at 18 and 48 h p.i. and adenoviral early (E1A 13s, E1B
19K, E1B 55K, E2A and E2B, E3 14.7K, E3 12.5K and E4 orf4/6) and late (L1) gene
expressionwas monitored by quantitative PCR. Results are normalized to GAPDH values
and expressed as relative fold change, having assigned an arbitrary value of 1 to mock
treated cells. Data are mean values of two experiments with duplicate samples; SD is
shown. Expression data are concordant with the genotype of the single adenoviral
mutants. In particular: i) in all cases the mutated viral genes are not expressed, ii) the
dl1004 infection cycle does not reach the late phase, iii) the dl337 has an accentuated
infectious cycle, while the dl520 and dl1520 have mildly attenuated cycles.treated) adenoviral particles. Inactive viruses were unable to induce
PRNP activation (Fig. 2) even when used at high dosage (moi 10000,
Fig. 2a). These results indicate that active viral infection is needed for
PRNP activation, which matches the second scenario indicated above;
conversely, the sole presence of viral DNA or of adenoviral proteins
was not sufficient for PRNP activation.
Fig. 4. Early viral gene expression is required for PRNP activation. Cells were infected
with Ad5 or with adenoviral mutants at a moi of 1000. a) mRNA was collected at 18
(black bars) and 48 h (grey bars) p.i. and PRNP mRNA was monitored by quantitative
PCR. Results are normalized to GAPDH values and expressed as relative fold change,
with an arbitrary value of 1 assigned to the mock sample collected at the 18 h time
point. Data are mean values of two experiments with duplicate samples; SD is shown.
For all viruses but H14, as compared to mock, pb0.05. For Ad5 versus dl520 at 48 h and
for Ad5 versus dl337 at 18 h, pb0.05. b) Protein extracts were collected at 18 h p.i. and
analyzed by western blotting using an anti-PrPC antibody and an anti-β tubulin
antibody as internal control. The band intensity (normalized to β tubulin) of Ad5, H14
and dl1004 were, respectively, 6fold, 1fold and 3fold the mock signals. In sum, viruses
competent for early gene transcription were able to activate PRNP.
Fig. 5. PRNP down-regulation aids adenoviral expression and replication. Cells were
infected with control lentivirus (LV-Scramble) or PrPC interfering lentivirus [LV-shPrP
(509–529) and LV-shPrP(391–411)], subjected to puromycin selection and (a) analyzed
by western blotting for PrPC expression; (b) super-infected with Ad5 and monitored for
adenoviral E2B mRNA (E2B cDNA) and genomic DNA (E2B gDNA) by quantitative PCR at
14 h and 40 h p.i. Quantitative PCR data are normalized to GAPDH values and expressed
as relative fold change, with an arbitrary value of 1 assigned to the Ad5-only treated
sample at the relative time point. Results are expressed as mean values of two
experiments with duplicate samples; SD is shown. Efficient and specific down-
regulation of PrPC obtained with the lentiviral vector directed towards PrPC favors
adenoviral early gene expression and improves adenoviral DNA replication. pb0.01 in
LV-shPrP versus LV-Scramble infected relative samples in all cases but in the E2B gDNA
sample collected at 14 h p.i.
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as well as in HuH7 (Fig. 2): this result implies that PRNP induction is
neither a specific event of the hepatic cell line HuH7, nor, more in
general, a response related to a transformed cell status (characteristic
of HuH7 but not of HUVEC).
Induction of PRNP by differently deleted adenoviral mutants
Having assessed that active adenoviral infection is required for
PRNP induction, we investigated which viral open reading frames
(orfs) were crucial to this process. A battery of adenoviral mutants
was thus selected and extensively characterized by quantitative PCR
for early and late gene expression at 18 and 48 h p.i. in HuH7 cells
(Fig. 3). The adenoviral mutants tested include the following: the
dl520 (dl13s; Haley et al., 1984), the dl337 (dlE1B 19K; Pilder et al.,
1984), the dl1520 (dlE1B 55K; Barker and Berk, 1987) and the dl1004
(dlE4; Bridge and Ketner, 1990). Expression data on specific
adenoviral orfs were concordant with the genotype of the single
adenoviral mutants. Indeed, none of the mutated viral genes were
expressed. In addition, dl1004 infected cells did not express L1 at
either 18 or 48 h, or any other orf at 48 h p.i.. This is concordant with
the blocking of the infectious process. This halting of the viral cycle
has been ascribed mainly to the formation of viral DNA concatemers,
which, in turn, is caused by the absence of the DNA repair machinery
counter-activation function orchestrated by the adenoviral E4
products (Bridge and Ketner, 1989; Carson et al., 2003). As already
described the dl520 and dl1520 have moderately attenuated cycles
because of the E1A 13s and E1B 55K deletions, respectively (Cherubini
et al., 2006; Haley et al., 1984). The dl520 can express the E1A 12 s
coding region, which partially compensates the E1A 13s functions
(Haley et al., 1984).Cells infected with Ad5 or with all adenoviral mutants but the fully
attenuated H14 (dlE1E3) did activate PRNP, as assessed by quantitative
PCR analysis of PRNP mRNA (Fig. 4a), both at 18 and 48 h p.i.
Interestingly, the timing of early gene expressionwas concordant with
that of PRNP induction. This is in particular suggested by the data
observed in cells infected with the dl520 mutant. This virus, as
described above, has a slower cycle, and unlike other mutants, has a
moderately higher impact on PRNP at 48 h p.i. than at 18 h p.i.
Western blotting on extracts from cells infected with Ad5, dl1004
or H14, further confirmed that early adenoviral expression activates
PRNP (Fig. 4b). Accumulation of PrPC was actually observed in cells
infected with the adenoviral mutant dl1004. Conversely, but in
accordance with mRNA data (Fig. 2), the fully attenuated mutant
H14 did not induce PrPC accumulation.
Taken together, these data suggest that early adenoviral gene
expression is needed for PRNP activation, while late gene expression
and viral production are not indispensable. Furthermore, among early
adenoviral products, the E4 (orfs 2, 3, 3/4, 6 and 6/7), the E1B 19K, the
E1B 55K and the E1A 13s are not strictly required for PRNP activation.
The PRNP activating candidate orfs thus appear to be restricted to the
E1A 12s, E2, and E4 orf1.
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In order to answer the question of whether the effect of Ad5 on
PRNP affected the viral cycle, a battery of recombinant lentiviruses
encoding short hairpin precursors of siRNA sequences directed
towards PRNP under control of H1 promoter and containing the
puromycin resistance coding sequence were produced and tested for
their ability to down-regulate PrPC (data not shown). The best
performing lentivirus were those encoding shRNAs directed towards
the region 509–529 or 391–411 of PRNP [LV-shPrP(509–529) and LV-
shPrP(391–411)]. As shown in Fig. 5a, cells infected with LV-shPrPs
showed efficient and specific down-regulation of PrPC as compared to
those infected with lentivirus coding for a scramble hairpin sequence
(LV-Scramble) or mock treated. Puromycin selected populations of LV-
shPrP or LV-Scramble infected cells, or untreated HuH7 were infected
with Ad5. Quantitative analysis of viral (E2B) mRNA and of genomic
adenoviral DNA content was performed 14 and 40 h after adenoviral
infection. PrPC reduction positively affected adenoviral replication and
adenoviral expression. Timing of activation by PrPC interference was
shifted for adenoviral DNA as compared to mRNA: mRNA accumula-
tionwas particularly evident at 14 h p.i., while viral DNA accumulation
was observed at 40 h p.i. (Fig. 5b). These results, taken together,
suggest an intracellular antiviral role for PrPC, possibly related to other
cell defense pathways.
Discussion
The interaction between viruses and PrPC has been investigated
in recent years in the context of two main frames: the exploitation of
viral infection as a way of investigating PrPC physiological functions,
and the search for a direct or indirect role of eukaryotic viruses in
PrPC related pathologies. Research in the latter area has led to the
commonly accepted concept that viral co-infection is not a necessary
condition for the development of prion diseases (Prusiner, 1998).
Nevertheless, different microbes have been shown to contribute to
the onset of TSEs (Ehresmann and Hogan, 1985; Leblanc et al., 2006;
Lotscher et al., 2003). The research field aimed at analyzing viral
components and viral infection to add insights to our knowledge of
PrPC physiological functions is an open area of investigation, since
the full characterization of the biological role of PrPC is still elusive.
Data indicate that the stress/defense response and the apoptotic
process are the main functions associated with PrPC linking this
protein to the modulation of viral infections. The question is more
difficult to interpret at the organism level where the immune
response creates a further stage of complexity in the analysis of
phenomena related to the reciprocal interaction between PrPCs and
viruses, nevertheless a link between PrPC induction, immune
response and viral replication has been assessed (Lotscher et al.,
2003, 2007; Nakamura et al., 2003; Nasu-Nishimura et al., 2008;
Thackray and Bujdoso, 2002a).
We observed that Ad5 infection of human liver carcinoma cell line
or of human umbilical vein endothelial cells induces a specific increase
in PRNP mRNA, and that this occurs in the early phase of infection
concomitantly with the transcription of early viral genes. The
induction of PrPC by Ad5 was observed at protein level too: this may
be a direct consequence of transcriptional activation, or else a
stabilization effect. Interestingly, a different result was observed for
total and membrane PrPC. We observed that, while at 18 h total PrPC
did accumulate on viral infection, and that this occurred to the same
extent as PRNPmRNA, at the membrane level, the adenoviral effect on
PrPC blew over at 18 h p.i. This suggests that membrane expression of
PrPC is not linearly correlated with PrPC mRNA or cytosolic expression
of the protein. These results are in agreement with data suggesting
that trafficking of PrPC to and from the cell surface is a complex
process subject to regulation through mechanisms that are as yet
unclear (Magalhaes et al., 2002a, 2002b).Importantly, PRNP mRNA up-regulation was not found to be
dependent on cell type or cell status. Both primary and transformed
human cells responded to adenoviral infection in terms of PrPC
activation, as well as cells of different tissue origin.
Our data indicate that Ad5 induced PRNP transcription, followed by
PrPC accumulation, is a process specifically determined by viral gene
expression: neither virus attachment, nor its internalization deter-
mined PrPC alterations, since neither a UV-inactivated virus nor an E1-
attenuated Ad5 were able to activate PRNP transcription. The analysis
of viral mutants allowed us to restrict the candidate viral functions
implicated in PRNP activation to the early genes E1A 12s, E2, and E4
orf1. Through the analysis of the dl1004mutant, which expresses early
orfs but most of the E4 region, and which neither completes the viral
cycle nor expresses late adenoviral orfs, we further observed that viral
production and late products are not indispensable in the process of
PrPC induction. These results are in line with the dominant role of
adenoviral early genes in the alteration of host cell biology preceding
viral production.
Among the orfs that are candidates for PrPC activation, the E1A 12s
could be suggested as key actor in the process. The E1A 12s accom-
plishes cell cycle deregulation by acting on transcriptional regulation
through the interaction with a number of host cell proteins that
function as transcription co-activators, including CBP/300, nucleoso-
mal remodeling factors (SWI/SNF) or comprise the general transcrip-
tion machinery (TBP) (Ben-Israel and Kleinberger, 2002). These effects
could be directly implicated in the modulation of PRNP, or,
alternatively, act indirectly on PrPC through the activation of other
cellular functions. Interestingly, it has been recently demonstrated
that an immune stimulus, including viral infection, can transactivate
endogenous retroviruses in mice and cells, which, in turn induces PrPC
(Lotscher et al., 2007). Adenoviral infection, and possibly the E1A 12s
protein, could induce endogenous retroviruses too, and consequently
activate PrPC. Further experiments are under way to elucidate the role
of E1A 12s in PRNP activation.
An effect of PrPC on viral cycles, and more in general a microbe/
prion interaction, has been previously described. Several agents are
implicated, including retroviruses (Leblanc et al., 2006; Lotscher et al.,
2007), Herpes simplex virus (Thrackay and Budjoso, 2002b), Coxsack-
ievirus B3 (Nakamura et al., 2003) the encelophalomyocarditis virus B
variant (Nasu-Nishimura et al., 2008), and the gram-negative
pathogen Brucella abortus (Watarai et al., 2003). Various roles are
hypothesized for PrPC in the different infectious processes. Taken
together the data in this field indicate that viral infection can be
influenced by PrPC modulation linked to the alteration in the cell or
organism of several processes, including apoptosis, cell cycle activa-
tion, interferon response, and activation of the immune system.
In order to assess whether PrPC actually plays a role of resistance to
adenoviral infection, we performed RNA interference experiments
with lentiviral vectors encoding hairpin sequences directed towards
PRNP. RNA interference worked efficiently to down-regulate the
protein, and, indeed, this system has been proposed as a strategy to
cure or prevent scrapie (Daude et al., 2003; Pfeifer et al., 2006), since
the reduction of the substrate protein for PrPSc, i.e. PrPC, is a general
approach conceived to combat the disease.
In cells down-regulated for PrPC we detected an increase in
adenoviral mRNA and DNA, which is concordant with other studies
suggesting that replication and release of infectious particles is
rendered more efficient by the absence of PrPC and is inhibited by
its over-expression (Lotscher et al., 2007; Nakamura et al., 2003),
indicating an antiviral role of PrPC.
Finally, this study is conceptually in accordance with data by
Ehresmann and Hogan (1985) describing how, in mice, the injection of
replication competent mouse Ad accelerates the onset of scrapie. The
contribution of Ad to scrapie observed by these authors could be
related to the Ad induced PrPC (cytosolic) production described
herein: PrPC (over-) expression is in fact considered the key factor
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al., 2006; Prusiner et al., 1998; Vilotte et al., 2001). In view of the high
incidence of adenoviral infection in the humanpopulation (Nwanegbo
et al., 2004), the fact that Ad infection has an effect on the PrPC and on
the onset of TSEs suggests a possible interest in conducting further
investigations in this field.
In conclusion, this study shows that adenoviral early genes activate
the transcription of PRNP as well as PrPC accumulation in the
cytoplasm and on the cell membrane, and PrPC expression appears
to control adenoviral replication. Our data add further insights to our
knowledge of PrPC functions as well as to the study of virus–prion
interactions.
Materials and methods
Cells
HuH7 (Nakabayashi et al., 1982), 293 (ATCC # CRL-1573), 293-T
(ATCC # CRL-11268) and HeLa cells (ATCC # CCL-2) were cultured in
complete medium (DMEM, Invitrogen, Carlsbad, CA) supplemented
with 10% FBS (Invitrogen). WI-62 cells (provided by G. Ketner, John
Hopkins University, Baltimore, MD) were cultured in MEM (Invitro-
gen) supplemented with 10% FBS (Invitrogen). Human umbilical vein
endothelial cells obtained from healthy patients (HUVEC, provided by
A. Orecchia, IDI, Rome, Italy) were cultured in EGM-2 (Clonetics, San
Diego, CA) supplemented with 10% FBS (Invitrogen). All cells were
maintained at 37 °C and 5% CO2.
Vectors and viruses
Stocks of wild type Ad5 (ATCC #VR-5) were prepared in HeLa cells
as previously described (Curiel and Douglas, 2002). H14 (dlE1E3
adenovirus, provided by Merck & Co. M.P. Neeper, Westpoint, PA)
(Sandig et al., 2000), dl520 (dl13s, provided by M. Crescenzi Istituto
Superiore di Sanità, Rome, Italy) (Haley et al., 1984), dl337 (dlE1B 19K,
provided by T. Shenk Princeton University, Princeton, NJ) (Pilder et al.,
1984) and dl1520 (dlE1B 55K, provided by A. Berk University of
Southern California, Los Angeles CA) (Barker and Berk, 1987) were
prepared in 293 cells. dl1004 (dlE4) was provided by G. Ketner (John
Hopkins University, Baltimore, MD) and prepared from WI-62 cells
(Bridge and Ketner, 1989). Briefly, all viruses were amplified in the
respective lines, cell pellets were collected 48 h post infection (p.i.)
and, after 3–5 freezing/thawing cycles, supernatants were purified on
CsCl gradients and desalted on PD-10 Sephadex G-25 columns
(Amersham Pharmacia, Uppsala Sweden). Stocks were titrated by
optical particle units (OPU) (Trapnell, 1993). The ratio between OPU
and plaque forming units (PFUs), in our hands, and according to
Mittereder et al. (1996) ranges from 9:1 to 245:1, depending on viral
preparation and on viral titration conditions. In all experiments theTable 1
Sequences used for quantitative PCR reactions
Target Sequence ref # Forw
Ad5 E1A 13s AY339865 GAG
Ad5 E1B 55K AY339865 GCT
Ad5 E1B 19K AY339865 GGC
Ad5 E2A AY339865 GGA
Ad5 E2B AY339865 GCC
Ad5 E3 14.7K AY339865 TTG
Ad5 E3 12.5K AY339865 CCG
Ad5 E4 orf4/6 AY339865 TGA
Ad5 L1 AY339865 GAG
PRNP NM_183079 AAT
GAPDH NM_002646 TGG
Forward and reverse sequences to be used in quantitative PCR were chosen on the indicatemultiplicity of infection (moi) is intended as OPU/cell. UV-inactivation
of Ad5 was performed as described (Gerba et al., 2002). Adenoviral
infections were performed by incubating cells for 1 h at 37 °C with
viruses diluted in DMEM supplemented with 2% FBS.
Second generation recombinant lentiviruses were produced by co-
transfection of 293T cells with the packaging vector pCMV-dR8.74
(15 μg/10 cm dish), the envelope vector pMD2.G (5 μg/10 cm dish), and
a transfer vector (20 μg/10 cm dish). The pCMV-dR8.74 and pMD2.G
plasmids were provided by D. Trono (Ecole Polytechnique Fédérale de
Lausanne, Switzerland). The transfer vector PLKO.1 puro-shScramble
(hairpin sequence: 5′ CCGGCAACAAGATGAAGAGCACCAACTCGAGTT-
GGTGCTCTTCATCTTGTTGTTTTT3′ Sigma, St. Louis, MO), PLKO.1
puro-shPrP (hairpin sequence: 5′ CCGGCCCATCATACATTTCGGCAGTC-
TCGAGACTGCCGAAATGTATGATGGGTTTTT3′, Sigma), and PLKO.1
puro-shPrP (hairpin sequence: 5′ CCGGTCAGTGGAACAAGCCGAGTAC-
TCGAGTACTCGGCTTGTTCCACTGATTTTT 3′, Sigma) were used, respec-
tively, for LV-Scramble, LV-shPrP (509–529), and LV-shPrP (391–411)
production. 48 and 72 h post transfection 293T supernatants were
collected and filtered as described (Piersanti et al., 2006). Lentiviral
titers were evaluated by p24 quantification (Alliance HIV-1 p24
antigen ELISA Kit Perkin Elmer, Boston, MA) following the manufac-
turer's instructions. Infections with recombinant lentiviruses were
performed at an moi of 2 pg p24/cell, in complete medium
supplemented with 8 μg/ml polybrene (Sigma). After viral addition,
cells were centrifuged for 30' at 1800 rpm, incubated 3 h at 37 °C, and
then transferred to fresh complete medium. 72 h p.i. cells were
subjected to selection in complete medium supplemented with 2 μg/
ml puromycin (Sigma) and kept under these conditions for further
analyses.
RNA extraction and preparation
Cells were lysed in situ at various times p.i. by addition of TRIzol
reagent (LifeTechnologies, Rockville, MD). Total RNAwas purified from
a TRIzol suspension according to the manufacturer's instructions;
after DNase treatment (Sigma), RNA was reverse transcribed into
cDNA with oligo d(T) primer and OMNISCRIPT RT KIT (Qiagen, Inc.,
Valencia, CA).
Quantitative PCR
To quantify viral DNA, cell and viral gene expression, primers
(Table 1) were selected using Primer Express software (Applied
Biosystems, Foster City, CA). Reactions were performed in a 25 μl
volume that included viral DNA [extracted from infected cell pellets
treated with 5 ng/μl proteinase K (Roche Diagnostics)] or the cDNA
sample, primers, and SYBR Green PCR Master mix (containing
nucleotides, AmpliTaq Gold DNA polymerase and optimized buffer
components, Qiagen). Quantitative PCR reactions were performed onard Reverse
GACCTGTGGCATGTTTGTC GTCCTAAAATGGCGCCTGCTA
GGCGCAGAAGTATTCCAT TATGCAAAGGTGGCACTTAGG
TCATCCCAGGCAAAGT GAAGAGCTTTTGAAATCCTGTGG
TACAGCGCCTGCATAAAAG CCAATCAGTTTTCCGGCAAGT
CTTGATGGAAGGCAATTT TCGCTTCCAACCCTCATCTTG
CCAACCAAGCGTCAGA GCTGCATTCACTCACCTTGTCA
GTGAGTTTTGCTACTTTGA AGCCTGATTCGGGAGTTTACC
TCCT CCAGTATGGTAGCGC CCGAGAT CGTGTTGGTC GTAGT
CAAAACCCAAATAGCAAGC ACTATGTTTAGCAGCGCATCCC
CAAGCAGCACACGGTCA TCGGTGAAGTTCTCCCCCTT
GCTACACTGAGCACCAG GGGTGTCGCTGTTGAAGTCA
d target sequences with the Primer Express software.
349P. Caruso et al. / Virology 385 (2009) 343–350an Applied Biosystems Prism 5700 sequence detection system. Cycle
threshold (Ct) values were exported directly into EXCEL worksheets
for analysis and the relative quantification was made using the 2−ΔΔCt
method (Tichopad et al., 2003). After cycling, a melting curve was
produced by slow denaturation of the PCR end products to validate the
specificity of amplification.
Western blotting for total PrPC quantification
Cell pellets were treated with lysis buffer [Tris–HCl 50 mM pH7.4,
10% NP-40, 0.25% NaDesoxycholate, EDTA1 mM, NaCl150 mM,
PMSF1 mM, protease inhibitor cocktail (Roche Diagnostics)]. After
freezing and thawing pellets were centrifuged 15' at 13,000 rpm at
4 °C and the supernatants collected. Sample reducing agent (NuPAGE
Invitrogen) and LDS sample buffer (NuPAGE Invitrogen) were added to
samples and the latter were loaded on to pre-cast 4–12% gradient
acrylamide gels (NuPAGE, Invitrogen). The run was performed in
MOPS running buffer and antioxidant (NuPAGE Invitrogen). Electro-
blotting on nitrocellulose filter (Amersham, Psicataway, NJ) was
performed in transfer buffer and antioxidant (NuPAGE Invitrogen).
After blocking in TBS–Tween 0.1%–Milk 5%, filters were incubated
with the anti-PrPC antibody [PrP (C-20) sc-7693, Santa Cruz
Biotechnology Inc.] and with the anti-βeta tubulin antibody (Santa
Cruz Biotechnology Inc.). Immunoreactive proteins were detected
using horseradish peroxidase conjugated secondary antibodies (Santa
Cruz Biotechnology Inc.) and revealed using the enhanced chemilu-
minescence system (ECL plus, Amersham Biosciences). Protein
quantification was performed with the Scion Image software (www.
scioncorp.com/): band intensities of the proteins of interest were
established, normalized to the relative β tubulin signals, and
differences among samples were expressed as the relative fold change
of normalized figures.
Flow cytometry analysis for membrane PrPC detection
Cells were harvested at various times p.i., detached using EDTA
solution 0.1 M, washed with PBS and blocked with PBS–5% FBS on ice
by shaking. After 1 h, cells were treated with the anti-PrPC antibody
(provided by V. Vetrugno Istituto Superiore di Sanità, Rome, Italy). 90'
incubations were performed in PBS–5% FBS by shaking on ice. Cells
were thenwashed four timeswith PBS and treatedwith the secondary
antibody FITC conjugated (BD Pharmingen™) by 1 h shaking on ice.
Cells were washed three times with PBS, resuspended in PBS, and
FACS analysis was performed using a FACSCalibur flow cytometer and
CellQuest software (Becton Dickinson Biosciences, San Diego, CA).
Statistical analysis
Datawere expressed asmean±SD. Statistical analysiswasperformed
using the t-test.
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